When analysing the seroconversion data in relation to the biological drugs used by the patients, it is relevant to point out that patients on anti-TNF treatment have a lower percentage of positive serology compared to other biologics (Ustekinumab and Vedolizumab), and this fact is maintained among those with known previous infection. The gene discussed is TNF; the disease is infection.